Bayer HealthCare today announced that the company will present latest preclinical data that introduce investigational compounds for both therapy and imaging in its oncology pipeline at the American Association for Cancer Research (AACR) 103rd Annual Meeting, March 31 – April 4, 2012, in Chicago, IL.
The annual AACR meeting highlights the latest findings in all major areas of cancer research.
This includes currently at Bayer developed investigational agents such as an antibody-drug conjugate (ADC, BAY 94-9343) and a phosphatidylinositol 3-kinase (PI3K) inhibitor (BAY 80-6946).
The antibody–drug conjugate Mesothelin-ADC is being developed to target the antigen mesothelin which is selectively expressed on certain tumours.
Mesothelin-ADC is developed in collaboration with ImmunoGen Inc.
The PI3K inhibitor targets a lipid kinase involved in crucial cellular functions such as tumour cell proliferation and survival signalling.
Both investigational agents are now in early clinical development (Phase I) at Bayer.
“Cancer is a complex disease process and as our understanding of these signalling mechanisms deepens, so does our ability to develop innovative, targeted approaches to combat this disease,” said Dr. Karl Ziegelbauer, Head of Therapeutic Research Group Oncology/Gynecological Therapy at Bayer HealthCare.
“The research data presented at this oncology research conference shows our commitment toward developing a wide variety of investigational agents against signaling pathways with the goal to treat cancer more effectively so patients can live longer.”